Gain Therapeutics announces common stock, warrants offering

Gain Therapeutics (GANX) announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock and warrants to purchase common stock in an underwritten public offering. All of the securities are being offered by the company. Gain intends to use the net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases, including GBA1 Parkinson’s disease, and for general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Newbridge Securities Corporation is acting as the sole book-running manager for the proposed offering.